BI-4020 is primarily investigated for its potential in cancer therapy, particularly non-small cell lung cancer (NSCLC), by targeting the epidermal growth factor receptor (EGFR) pathway involved in tumor growth and survival. It is being studied for its ability to inhibit EGFR, a protein that plays a critical role in cancer cell proliferation and metastasis. Researchers are exploring its use in combination with other therapies to enhance treatment efficacy and overcome drug resistance. Additionally, preclinical studies are assessing its safety profile and optimal dosing for potential clinical applications. Its development represents a promising approach to precision medicine in oncology.